Australian biotech market today 15.04.09
Wednesday, 15 April, 2009
The healthcare index was a bright spot on an otherwise poor day for listed stocks, up 0.32 per cent at 3.30pm today.
Drug delivery company Acrux (ASX:ACR) is up 7c to 70c following yesterday’s ruling that it resume mediation with its US licensee, Vivus, over beginning a Phase III trial of its testosterone spray for women, Luramist.
Alchemia (ASX:ACL) was up 3.5c to 34c while Atcor (ASX:ACG) is up a cent to 21c on today’s news that it has signed two more sales contracts for its SphygmoCor blood pressure systems, bringing total contracts in the past year to US$7.3 million.
Circadian (ASX:CIR) was down a touch, while Cellestis (ASX:CST) lost some of yesterday’s gains, settling at $2.60.
Pharmaxis (ASX:PXS) has regained some of yesterday’s losses and is back over $2.00, while Mesoblast (ASX:MSB) is up a little.
Cochlear (ASX:COH) is down almost a dollar, while CSL (ASX:CSL) is up 40c and ResMed (ASX:RMD) is up 23c.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
